MGRX.NASDAQMangoceuticals, INC
10-Q: Mangoceuticals Reports Third Quarter 2024 Results, Revenue Declines Amid Platform Transition
Sentiment:
Quarterly Report
Mangoceuticals, Inc. reports a net loss of $1.99 million for the third quarter of 2024, with a decrease in revenue due to platform migration issues.
Capital raiseThe company anticipates the need for additional funding to continue operations.The company may seek additional funding through equity financings, debt financings or other capital sources.The company expects to raise a portion of its funding pursuant to the SPA and ELOC.The company may also seek to acquire additional businesses or assets in the future, which may require it to raise funding.
Worse than expectedThe company's revenue decreased significantly in the third quarter of 2024 compared to the same period in 2023.The company's net loss increased in the third quarter of 2024 compared to the same period in 2023.The company's cash and cash equivalents decreased significantly.
Summary
- Mangoceuticals, Inc. reported a net loss of $1.99 million for the three months ended September 30, 2024, compared to a net loss of $1.79 million for the same period in 2023.
- The company's revenue decreased to $133,368 for the third quarter of 2024, down from $245,160 in the third quarter of 2023, primarily due to issues arising from a platform migration.
- Operating expenses totaled $1.84 million for the quarter, a slight decrease from $1.94 million in the same quarter of the previous year.
- For the nine months ended September 30, 2024, the company's net loss was $6.75 million, compared to $6.64 million for the same period in 2023.
- Revenue for the nine months ended September 30, 2024, was $510,626, a slight increase from $487,119 for the same period in 2023.
- The company's cash and cash equivalents decreased to $73,912 as of September 30, 2024, from $739,006 at the end of 2023.
- The company has a working capital deficit of $1.3 million as of September 30, 2024.
- The company completed a 1-for-15 reverse stock split on October 16, 2024.
- The company purchased patents for $20 million, paid through a combination of Series C Preferred Stock and cash.
- The company has entered into a Master Distribution Agreement with ISFLST, Inc. for distribution in Asia Pacific and Latin America.
Sentiment
Score: 3
Explanation: The document presents a concerning financial picture with declining revenue, increasing losses, and a significant decrease in cash. While there are some positive developments, the overall sentiment is negative due to the company's financial instability and need for additional funding.
Positives
- The company's revenue for the nine months ended September 30, 2024, increased slightly to $510,626 from $487,119 in the same period of 2023.
- Operating expenses decreased slightly for both the three and nine month periods ended September 30, 2024.
- The company has secured a Master Distribution Agreement with ISFLST, Inc. for expansion into Asia Pacific and Latin America.
- The company has acquired patents related to infection prevention.
Negatives
- The company experienced a significant decrease in revenue for the third quarter of 2024, down 45.6% year-over-year.
- The company's net loss increased for the third quarter of 2024 compared to the same period in 2023.
- The company's cash and cash equivalents have decreased significantly.
- The company has a working capital deficit of $1.3 million as of September 30, 2024.
Risks
- The company's ability to continue as a going concern is in doubt due to recurring losses and a working capital deficit.
- The company needs to raise additional capital to fund operations and execute its business plan.
- The company's reliance on related party transactions poses a risk.
- The company's products are not FDA approved and are sold under an exemption, which may be challenged.
- The company faces competition and needs to build a well-known brand name.
- The company is subject to risks associated with inflation, interest rates, and economic downturns.
- The company is subject to risks associated with data security breaches and unauthorized access to confidential information.
- The company is subject to risks associated with intellectual property protection and potential litigation.
- The company is subject to risks associated with government regulations and compliance.
- The company is subject to risks associated with the rights and preferences of outstanding preferred stock, including liquidation preferences and dilution.
- The company is subject to risks associated with the volatile nature of the trading price of its common stock.
- The company is subject to risks associated with the potential for future sales of securities causing dilution.
- The company is subject to risks associated with the potential for a change of control.
- The company is subject to risks associated with the potential delisting of its common stock from Nasdaq.
Future Outlook
The company anticipates the need for additional funding to continue operations and is exploring strategic alternatives. The company plans to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand its operations organically or through acquisitions as funding and opportunities arise. The company also plans to continue to make additional and ongoing technology enhancements to its platform, further develop, market and advertise additional mens health and wellness related products on its telemedicine platform, and identify strategic acquisitions that complement its vision.
Industry Context
The company operates in the growing telemedicine and men's wellness sector, focusing on products for erectile dysfunction, hair loss, testosterone replacement, and weight management. The company's reliance on compounding pharmacies and the sale of non-FDA approved products is a common practice in this industry, but also carries regulatory risks. The company's expansion into international markets through a distribution agreement is a typical strategy for growth in this sector.
Comparison to Industry Standards
- The company's revenue growth is below the average for the telemedicine industry, which has seen significant growth in recent years, however, the company's revenue growth is impacted by the platform migration issues.
- The company's net losses are higher than some of its competitors, indicating a need for improved cost management and revenue generation.
- The company's reliance on related party transactions is higher than industry standards, which may raise concerns about conflicts of interest.
- The company's cash burn rate is higher than some of its competitors, indicating a need for additional funding.
- The company's acquisition of patents is a positive step, but the long-term value of these patents remains to be seen.
- The company's entry into a distribution agreement is a positive step, but the success of this agreement will depend on the company's ability to execute its strategy.
Legal Proceedings
- The Company learned that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against the Company claiming that the Company improperly copied its weight-loss medicine, Zepbound and Mounjaro.
Related Party Transactions
- The company has significant related party transactions with Epiq Scripts, LLC, a pharmacy and compounding service provider owned by the company's CEO.
- The company has received loans from related parties, including the CEO and an entity owned by the CEO.
- The company has prepaid expenses with a related party.
Stakeholder Impact
- Shareholders face significant dilution from the conversion of preferred stock and the exercise of warrants.
- Shareholders face the risk of a decrease in the value of their stock due to the company's financial instability and need for additional funding.
- Shareholders face the risk of a delisting of the company's common stock from Nasdaq.
- Employees may face uncertainty due to the company's financial instability.
- Customers may face uncertainty due to the company's financial instability.
- Creditors may face uncertainty due to the company's financial instability.
Next Steps
- The company will continue to make additional and ongoing technology enhancements to its platform.
- The company will further develop, market and advertise additional mens health and wellness related products on its telemedicine platform.
- The company will identify strategic acquisitions that complement its vision.
- The company will continue to pursue an aggressive growth strategy for the expansion of operations through marketing to attract new customers for Prime and its Compounded Products.
- The company will continue to evaluate strategic alternatives for the Company.
Key Dates
| Date | Description |
|---|---|
| 2021-12-10 | Company received advances of $39,200 from American International Holdings Corp. |
| 2022-03-18 | Company received advances of $50,000 from American International Holdings Corp. |
| 2022-06-16 | Cohen Enterprises, Inc. entered into a Stock Purchase Agreement for the purchase of 533,333 shares of the outstanding common stock of the Company. |
| 2022-06-29 | Company received an advance of $25,000 from Cohen Enterprises. |
| 2022-08-18 | Company repaid Cohen Enterprises $25,000. |
| 2022-09-28 | Company entered into a lease agreement for office space. |
| 2022-11-18 | Company entered into a note payable with a vendor for the purchase of equipment. |
| 2023-03-20 | Company completed its initial public offering (IPO). |
| 2023-04-04 | Company repaid Cohen Enterprises $89,200. |
| 2023-09-01 | Company entered into a service agreement with Greentree Financial Group, Inc. |
| 2023-10-01 | Company executed a Consulting Agreement with Gene Johnston. |
| 2023-10-10 | Company entered into a Consulting Agreement with Luca Consulting, LLC. |
| 2023-11-01 | Company entered into an Influencer Agreement with Jason Szkup and appointed Dr. Douglas Christianson to the Advisory Board. |
| 2023-11-15 | Company renewed a Consulting Agreement with PHX Global, LLC. |
| 2023-12-11 | Company entered into a Marketing Agreement with Marius Pharmaceuticals. |
| 2023-12-15 | Company entered into an underwriting agreement with Boustead Securities, LLC for a follow-on offering. |
| 2023-12-19 | Company closed the follow-on offering. |
| 2024-01-02 | Company entered into a Consulting Agreement with G&P General Consulting. |
| 2024-01-10 | Company renewed a Consulting Agreement with Luca Consulting, LLC. |
| 2024-01-11 | Company entered into a Consulting Agreement with First Level Capital. |
| 2024-01-18 | Underwriters exercised their over-allotment option in full to purchase an additional 40,000 shares of common stock. |
| 2024-01-22 | Sale of additional 40,000 shares of common stock closed. |
| 2024-02-07 | Company issued G&P General Consulting another 16,667 shares of restricted common stock. |
| 2024-03-01 | Company borrowed $37,500 from Ronin Equity Partners. |
| 2024-03-18 | Company borrowed $50,000 from Cohen Enterprises. |
| 2024-03-21 | Company entered into an Amendment to the Consulting Agreement with Luca and a Consulting Agreement with Zvonimir Moric. |
| 2024-03-28 | Company designated 6,000 shares of Series B Convertible Preferred Stock. |
| 2024-04-01 | Company borrowed $100,000 from Cohen Enterprises. |
| 2024-04-04 | Company agreed to definitive terms on a Securities Purchase Agreement with an institutional accredited investor. |
| 2024-04-05 | Initial Closing Date of the Securities Purchase Agreement. |
| 2024-04-08 | Company entered into an Equity Purchase Agreement with the Purchaser. |
| 2024-04-18 | Company designated 6,250,000 shares of 6% Series C Convertible Cumulative Preferred Stock. |
| 2024-04-24 | Company entered into a Patent Purchase Agreement with Intramont Technologies, Inc. |
| 2024-04-25 | Company amended its Consulting Agreement with PHX Global, LLC. |
| 2024-04-26 | Company partially closed the second closing under the Securities Purchase Agreement. |
| 2024-04-28 | Company and the Purchaser entered into an Omnibus Amendment Agreement No. 1. |
| 2024-05-15 | Company disposed of equipment to Epiq Scripts. |
| 2024-05-17 | Company closed the remaining portion of the Second Closing under the Securities Purchase Agreement. |
| 2024-05-21 | Purchaser converted 50 shares of Series B Preferred Stock into 18,062 shares of common stock and Company sold 16,667 shares of common stock to the Purchaser. |
| 2024-05-22 | Purchaser converted 155 shares of Series B Preferred Stock into 55,993 shares of common stock and Company sold 46,667 shares of common stock to the Purchaser. |
| 2024-05-23 | Company entered into a Consulting Agreement with Acorn Management Partners, L.L.C. |
| 2024-05-24 | Purchaser converted 150 shares of Series B Preferred Stock into 54,187 shares of common stock. |
| 2024-06-05 | Board of Directors issued 83,333 shares to certain officers, directors and employees. |
| 2024-06-27 | Company amended the Series B Designation. |
| 2024-06-28 | Company sold the Purchaser 750 shares of Series B Preferred Stock and warrants. |
| 2024-07-09 | Purchaser converted 135 shares of Series B Preferred Stock into 35,779 shares of common stock and Company entered into a Master Distribution Agreement with ISFLST, Inc. |
| 2024-07-12 | Company granted 13,333 options to purchase shares of common stock to Raffi Sahul. |
| 2024-07-22 | Company entered into a Consulting Agreement with John Dorsey. |
| 2024-07-24 | Purchaser converted 50 shares of Series B Preferred Stock into 2,245 shares of common stock. |
| 2024-08-22 | Company entered into Consulting Agreements with Levo Healthcare Consulting, Inc. and Veritas Consulting Group, Inc. |
| 2024-08-26 | Company partially closed the Fourth Closing under the Securities Purchase Agreement. |
| 2024-09-10 | Company entered into amended Consulting Agreements with Luca Consulting LLC and Zvonimir Moric. |
| 2024-09-26 | Company partially closed the Fourth Closing under the Securities Purchase Agreement and Purchaser converted 140 shares of Series B Preferred Stock into 47,903 shares of common stock. |
| 2024-09-27 | Company extended a Consulting Agreement with PHX Global, LLC. |
| 2024-10-01 | Company delivered an Advance Notice to the Platinum Point Capital and sold 166,667 shares of common stock. |
| 2024-10-02 | Platinum Point Capital converted 190 shares of Series B Preferred Stock into 66,923 shares of common stock. |
| 2024-10-07 | Company repaid $37,500 that was borrowed from Ronin Equity Partners. |
| 2024-10-08 | Company filed a Certificate of Amendment to its Certificate of Formation to affect the Reverse Stock Split. |
| 2024-10-16 | Company completed a 1-for-15 reverse stock split. |
| 2024-10-18 | Platinum Point Capital converted 200 shares of Series B Preferred Stock into 93,299 shares of common stock and Company entered into a $150,000 promissory note with Cohen Enterprises, Inc. |
| 2024-10-21 | Company learned that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against the Company. |
| 2024-10-24 | Company delivered an Advance Notice to Platinum Point Capital and sold 33,333 shares of common stock. |
| 2024-11-11 | Company entered into a renewal of the Consulting agreement with Eugene M. Johnston. |
| 2024-11-14 | Date of this report. |
Keywords
telemedicine, mens wellness, erectile dysfunction, hair loss, testosterone replacement therapy, weight management, pharmaceuticals, compounding pharmacy, FDA, reverse stock split, preferred stock, warrants, dilution, liquidation preference, patent, distribution agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.